Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

por Bahleda, R., Meric-Bernstam, F., Goyal, L., Tran, B., He, Y., Yamamiya, I., Benhadji, K. A., Matos, I., Arkenau, H.-T.
Publicado 2020

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells

por Serova, M, Galmarini, C M, Ghoul, A, Benhadji, K, Green, S R, Chiao, J, Faivre, S, Cvitkovic, E, Le Tourneau, C, Calvo, F, Raymond, E
Publicado 2007

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells

por Benhadji, K A, Serova, M, Ghoul, A, Cvitkovic, E, Le Tourneau, C, Ogbourne, S M, Lokiec, F, Calvo, F, Hammel, P, Faivre, S, Raymond, E
Publicado 2008

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer

por Van Cutsem, E., Hochster, H., Shitara, K., Mayer, R., Ohtsu, A., Falcone, A., Yoshino, T., Doi, T., Ilson, D.H., Arkenau, H.-T., George, B., Benhadji, K.A., Makris, L., Tabernero, J.
Publicado 2022

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

por Even, C., Lassen, U., Merchan, J., Le Tourneau, C., Soria, J-C, Ferte, C., Ricci, F., Diener, J. T., Yuen, E., Smith, C., Oakley, G. J., Benhadji, K. A., Massard, Christophe
Publicado 2019

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

por Kelley, R.K., Gane, E., Assenat, E., Siebler, J., Galle, P.R., Merle, P., Hourmand, I.O., Cleverly, A., Zhao, Y., Gueorguieva, I., Lahn, M., Faivre, S., Benhadji, K.A., Giannelli, G.
Publicado 2019